Advanced Medical Institute, Inc.(fka AVMD)

http://www.amiaustralia.com.au/
http://www.avmd.com.au

 Mission Statement

Advanced Medical Institute Inc. (collectively with its subsidiaries, “AVMD”) focuses on delivering safer, faster acting and lower dosage treatments to people suffering from impotence and premature ejaculation. Unlike many of our competitors, we treat the whole patient, individually and over the long term. AVMD’s strategy is to provide new methods of treatment and delivery systems that provide a practical non-invasive method of drug delivery to the body and by using existing drug products with known safety and efficacy. We market directly to the public. All medications are provided under individual prescriptions and our treatments are only available through our dedicated clinics under the supervision of trained medical personnel. At present our treatments are only available in Australia, New Zealand, China and the United Kingdom.

Company

AVMD, headquartered in Sydney, Australia, is a publicly held Nevada corporation that currently trades on the over-the-counter (bulletin board) market under the symbol AVMD.OB. AVMD operates primarily through its wholly-owned Australian subsidiary, AMI Australia. Please click here to access our current corporate structure chart. AVMD currently has approximately 53.5 million issued shares.Please click here to obtain further information on AVMD’s issued capital and a copy of AVMD’s financial reports.

Future Goals

 One of AVMD’s goals is to extend the reach of our innovative treatment programs beyond Australia, New Zealand, China and the United Kingdom. We are exploring growth opportunities in Asia, Europe and the United States and on September 15, 2008, we announced expansion of our operations to the United Kingdom where we opened up our treatment centers, contracts with independent doctors and pharmacies and began airing infomercials throughout the country.

Based on publicly available Australian and Worldwide market information, the sexual dysfunction market share we have achieved in Australia and our analysis of the regulatory and market opportunities available in the United States and elsewhere, we are extremely excited by our prospects and our opportunities for growth in the coming years.

 Latest 10Q Ending Sept 30, 2009

Assets

 AVMD’s wholly owned subsidiary, AMI Australia operates a centralized call center and twenty medical centers and sales offices throughout Australia, New Zealand, China and the United Kingdom.

AVMD’s core assets includes significant unique proprietary intellectual property developed during our subsidiaries’ business 16 years operating history. Our proprietary intellectual property includes:

•  Customer database of more than 400,000 patients.
•  Clinic Management System software (CMS) & Web based Clinic Management System software (CMS Web) which provides:
  • Customer profiles;
  • Financial history and management systems; 
  • Logistics management; 
  • Customer Relationship Management (CRM);
  • Clinic booking system; and
  • Micro-management and internal controls.
• Specific drug formulations.
• Dosing protocols, treatment manuals and methodologies.
• An Australian innovation patent (Australian Innovation Patent No 2005100183, which patent is due to expire on July 9, 2012), an Australian standard patent application (Australian standard patent application No. 2004222783), a worldwide PCT patent application Patent No PCT/AU2004/000931 (WO 2005/004855 A1)) filed with IP Australia and the subsequent individual country applications filed in the United States, Europe, Japan, the People’s Republic of China, India and New Zealand. The patents relate to various methods of treatment delivery via nasal (mucosal) inhalation and topical application of certain formulations used in AVMD’s treatments for premature ejaculation. The patents and associated formulations are integral to those treatments. AVMD’s impotence and erectile dysfunction treatments are not patent protected.
• Call center scripts.
• • Marketing and sales collateral including copyright in our advertisements.
  • Business trademarks
  • Additional trade secrets, technical information and detailed market knowledge and understanding.
• Ownership of Intellectual Medical Technologies Pty Limited (IMT).

 Management

Dr. Jack Vaisman Founder President, Chief Executive Officer and Chairman of the Board of Directors	Dr. Vaisman is the chief executive officer and a director of AVMD. Dr. Vaisman is a pioneer in the treatment of sexual dysfunction (impotence and premature ejaculation) in Australia. Since 2001, he has served as the Managing Director and Chief Executive Officer of AMI Australia, AVMD’s chief operating subsidiary. He is responsible for the overall management and strategic direction of AMI Australia's business operations. Dr. Vaisman was also the Founder and Director of On Clinic International in Australia. The holder of a Bachelor of Medicine, a Master of Gynaecology and a PhD in Medical Science, he has more than 35 years of experience and expertise in the field of sexual health care and was recently granted an innovation patent relating to the treatment of premature ejaculation by the Australian patent office.
Tony Khan Executive Vice President, Chief Operations Officer	Mr. Khan is AVMD’s Chief Operating Officer. Mr. Khan has served as Secretary and a Director of the Company since April 7, 2005. Mr. Khan also served as the chief operating officer of AMI Australia since July 1, 2005. From 2001 to July 1, 2005, Mr. Khan was the General Manager of AMI Australia, AVMD’s chief operating subsidiary. Previously, Khan founded, was the director and was the sole shareholder of Australian Momentum Health Pty Limited, a provider of impotency treatments in Australia and a predecessor of AMI Australia. Before founding Australian Momentum Health, he was Sales Manager and Operations Manager for On Clinic International Pty Limited. Mr. Khan holds a Masters degree in Commerce and Accounting and has been involved in the sexual dysfunction industry for over 10 years.
Dilip Shrestha Chief Financial Officer	Mr. Shrestha is the Chief Financial Officer of AVMD. Mr. Shrestha joined AMI Australia, AVMD’s chief operating subsidiary, in 2001 as a financial controller and was named Chief Financial Officer of AVMD on April 7, 2005. Prior to joining AMI Australia, he was a financial officer with Australian Momentum Health Pty Limited (a predecessor company of AMI Australia), a position he held from 1999 until 2001. He began his career as an operations and information technology manager with Kalinchowk Trading Company Ltd. Mr. Shrestha holds a Master’s degree in E-Commerce, a Graduate Diploma of Information Systems and E-Commerce and a Bachelor of Business Accounting. Mr. Shrestha is the co-developer of AVMD’s in-house proprietary enterprise software which is designed to oversee and manage AVMD’s business operations and which incorporates a customer management system that tracks customers from first contact to treatment program completion.

SHARE STRUCTURE

As of November 23, 2009

Authorized Shares: 100,000,000
Outstanding Shares: 53,507,450
Float: 30,240,450